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substance of the wide range of problems, heterogeneous
populations, and differing circumstances faced by deci-
sion-makers has yet to be justified.
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OBJECTIVES:
 
 Clinical trials have demonstrated that
treatment can reduce the risk of osteoporosis-related
fractures in women over 50 years by 40%. The benefits
of treatment may be much lower due to lack of adherence
to treatment. Up to 20% of chronically ill patients fail to
initially fill their prescriptions, and 50% are noncompli-
ant after one year. We evaluated the feasibility of using a
database to estimate the relation between the occurrence
of fractures and adherence to osteoporosis medication in
actual practice.
METHODS: Major issues that were examined included:
whether there were sufficient subjects who received os-
teoporosis medication in the database; whether fracture
risk can be estimated in this population; how to deter-
mine whether a subject was covered for a given period
based on dispensing rather than prescribing data; when a
dispensing gap indicated non-persistence.
RESULTS: A community database of seven linked files
from Saskatchewan covering over 99% of its 1.1 million
residents was judged sufficiently large: 6,165 females older
than 45 were diagnosed in 2000 as ICD9 code 733, which
includes osteoporosis. Bisphosphonates were added to the
formulary in 1996. In 2000, 10,720 patients filled pre-
scriptions for the most widely used bisphosphonate and
33,585 filled prescriptions for conjugated estrogen. Physi-
cians or hospitals treated 12,765 females for fractures. Ad-
herence data were not available. A logical algorithm was
developed to determine persistence. It combined informa-
tion on minimally effective dose and maximum daily dos-
age with quantity, dose, dispensing date, drug type, and
tablet scoring, allowed for accumulation of medications
for later use, and corrected for hospitalizations.
CONCLUSIONS: The relation of fractures to adherence
with osteoporosis therapy can be studied through analy-
sis of this database using the algorithm.
 
PMI12
 
CAREGIVER-BURDEN MEASURES IN 
ALZHEIMER’S DISEASE: A
COMPREHENSIVE REVIEW
Borenstein J
 
1
 
, Chang S
 
2
 
, Cohen A
 
2
 
, Reyes E
 
1
 
, Russak SM
 
1
 
, 
Chiou CF
 
3
 
1
 
Cedars-Sinai Health System, Zynx Health Incorporated, 
Beverly Hills, CA, USA; 
 
2
 
Novartis Pharmaceutical Corporation, 
East Hanover, NJ, USA; 
 
3
 
Zynx Health Inc.-a subsidiary of 
Cedars-Sinai Health System, Beverly Hills, CA, USA
 
OBJECTIVES:
 
 To review and assess current measures of
caregiver burden in Alzheimer’s Disease (AD).
 
METHODS:
 
 A systematic search of MEDLINE, HEALTH-
STAR, and PUBMED databases was conducted to identify
all disease-specific and general caregiver-burden measures
used within the AD population. The accuracy and ultimate
value of a measure was assessed through three general psy-
chometric indices of performance: reliability; validity, and re-
sponsiveness. The evaluation of caregiver-burden instruments
along these psychometric properties were identified and com-
pared across measures.
RESULTS: A total of 62 articles were found to contain
background information or application of AD caregiver-
burden measures. Of these articles, ten measures were iden-
tified. Four were AD-specific and six were generic measures
used within the AD population. The available evidence of
each measure’s reliability, validity and responsiveness var-
ied. The Screen for Caregiver Burden (SCB) was the only
measure that reported reliability, construct and content va-
lidity, and responsiveness and performed well.
CONCLUSIONS: The lack of psychometric properties
reported in the majority of measures may limit the ability
to accurately assess caregiver burden and to evaluate
changes in response to interventions intended to lessen
this burden. Future validation studies of AD caregiver
measures will benefit by addressing these issues.
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OBJECTIVES: More than 40 EQ-5D have been evalu-
ated using a standardized time trade-off (TTO) protocol
in large-scale samples of the general public from the
United Kingdom (N  3395), Spain (N  979), and Ger-
many (N  339). This has created the first opportunity
to perform a large-scale comparison of TTO values be-
tween countries. This manuscript reports the mutual ef-
forts of several research groups within the EuroQol
Group to make such comparisons.
METHODS: Variation between the samples with respect to
background variables was controlled by multilevel analysis.
RESULTS: There are differences in TTO of health states:
the Spanish TTO values resemble the British, but the Ger-
man values are higher. The differences in TTO values are
larger than the small differences found in similar interna-
tional comparisons of VAS-based valuations. The differ-
ences found in the TTO can be explained in part by dif-
ferences in the distribution of background variables.
These results suggest that health is valued differently by
the three populations when measured using TTO, al-
though the differences are small. The differences found
seem to be driven by differences in the proportion and
the magnitude of negative health-state valuations. These
426 Abstracts
differences in negative values could be the result of cul-
tural differences or due to small differences in the opera-
tionalization of TTO.
CONCLUSION: The differences in the value of health
between the European countries seem to be small. This
opens the door for a European tariff for the EQ-5D,
which might facilitate QALY-analysis in international tri-
als considerably.
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OBJECTIVES: It is commonly assumed that the gold
standard method for producing new language versions of
patient-completed outcome measures is to translate using
back-translation. This paper will demonstrate that trans-
lation alone is insufficient and that back-translation is an
inherently flawed methodology.
METHODS: Literature review.
RESULTS: Back-translation fails to take account of the
complexity of nuances and meanings inherent in lan-
guage. While we might get back to where we started, it
does not imply that we have traveled by the appropriate
route. Back-translation can only succeed where straight-
forward semantic and conceptual equivalents exist in the
target language. In such a case, the method is likely to
have been an unnecessary expense. A further problem is
the reliance on bilinguals. Their social and health status
are likely to be higher than average, making them unrep-
resentative of the patient population. Thus, their use
should be restricted to producing a first draft translation.
This translation then needs to be assessed by people more
typical of the average patient participant, working in
their own language. The acceptability of this final version
also needs to be tested with relevant patients to confirm
comprehension and acceptability. However, adaptation
involves both the translation and psychometric testing of
an instrument for a new culture. It remains necessary to
test the psychometric properties of the translation for-
mally before it is used in a trial. The new version should
be shown to have acceptable reproducibility and con-
struct validity. Item response theory should also be ap-
plied to ensure that cultural response bias does not exist.
CONCLUSIONS: Back-translation by bilinguals cannot
guarantee that a translated questionnaire will be accept-
able to the target audience. Translation alone is not suffi-
cient to ensure that the new language version is suitable
for use in a clinical trial.
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Determining the best method for cost analysis of end-of-
life care regimens requires a systematic approach for con-
necting the research question being addressed with the
data requirements and analyses. There are several guiding
principles to direct this research, specifically in the areas
of sensitivity analysis, uncertainty, generalizability, and
measurement of efficiency such as cost-benefit or cost-
utility. There exists a body of literature in which disease-
specific or system-wide costing of health care is de-
scribed, but few apply to end-of-life care.
OBJECTIVE: To investigate, evaluate and present cost-
analysis methods through a synthesis of recently pub-
lished literature, and the implications of applying these
methods to ongoing clinical studies.
METHODS: Cost analyses include those acquired from
articles published in professional journals in the area of
cost, cost analysis and end-of-life care and applied to a
set of on-going clinical studies.
RESULTS: Based on a sample of nearly 30,000 cost stud-
ies in which few consider end-of-life care, at least eight
methods for examining costs of care are defined. On one
end of the spectrum is the micro-costing method in which
all personnel time, supplies, cost of facilities, pharmaceuti-
cals, lab expenses and all other patient services conducted
are tracked and costed using a variety of codes. On the
other end is the attributable costing method that uses ag-
gregate and average costs for inpatient and outpatient care
as well as for procedures and drugs associated with the
corresponding diagnosis and treatment. Only newly initi-
ated studies can feasibly employ micro costing. On-going
studies require abstracting from other methods.
CONCLUSIONS: In light of the national concern over
costs associated with end-of-life care, efforts are needed
to amalgamate guidelines and methodologies in this area
in order to provide a useful and accessible resource to
conduct meaningful cost-analysis research.
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OBJECTIVES: The aim of our research has been the valu-
ation of informal care. Informal care plays a substantial
role in the total care provided to patients with chronic dis-
eases. However, at this moment informal care is hardly in-
corporated in economic evaluations of health care. Espe-
cially the combination of the costs (time invested and
household expenditures) and effects (health-related quality
of life of informal care giving) is innovative.
METHODS: The data were collected by mailed question-
naires to primary informal caregivers in an evaluation of
Dutch integrated stroke service experiments, at two mo-
ments in time. The sample size is 217 informal caregivers
(two months after stroke) and 158 caregivers (six months
after stroke). We used a questionnaire including a range of
items on different informal care tasks. Health related quality
of life was measured with the EuroQol (EQ#64979; 5).
